Clinical trial
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
NCT00602511 is registered in ClinicalTrials.gov with Nordic Myeloma Study Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
- Lead sponsor
- Nordic Myeloma Study Group
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2007
- Completion date
- December 31, 2010
- Enrollment
- 300 (estimated)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.